A Rare Complication: Development of an Aspergilloma after Endobronchial Coil Placement in a COPD Patient.


Journal

Respiration; international review of thoracic diseases
ISSN: 1423-0356
Titre abrégé: Respiration
Pays: Switzerland
ID NLM: 0137356

Informations de publication

Date de publication:
Historique:
received: 05 08 2019
accepted: 14 09 2019
pubmed: 18 10 2019
medline: 22 4 2021
entrez: 18 10 2019
Statut: ppublish

Résumé

Endobronchial coils are a relatively novel endoscopic lung volume reduction modality that aims to increase functional capacity in chronic obstructive pulmonary disease (COPD) patients. Two major trials have studied the safety and efficacy of this therapy, but long-term safety has not been studied. Adverse events reported are mainly periprocedural pneumothoraces and early bacterial infectious complications. We report the case of a patient with severe emphysema (Global Initiative for Chronic Obstructive Lung Disease stage IV COPD) who developed endobronchial coil-associated aspergillomas 3 years after coil placement.

Identifiants

pubmed: 31622972
pii: 000503363
doi: 10.1159/000503363
doi:

Substances chimiques

Antifungal Agents 0
Voriconazole JFU09I87TR

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

423-425

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Alexandre Plante (A)

Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Québec, Canada.

Julien Guinde (J)

Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Québec, Canada.
Department of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, Marseille, France.

Christine Boudreau (C)

Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Québec, Canada.

François Maltais (F)

Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Québec, Canada.

Simon Martel (S)

Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Québec, Canada.

Antoine Delage (A)

Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Québec, Canada.

Marc Fortin (M)

Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Québec, Canada, marc.fortin@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH